Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this interesting session on Indian Patient Experience on Adalimumab
Adalimumab, a widely used biologic for treating various autoimmune conditions, has garnered positive feedback from Indian patients for its efficacy in managing diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Patients report significant improvements in symptom relief, including reduced pain, swelling, and skin lesions, leading to enhanced quality of life. This biologic’s ability to provide rapid and sustained symptom control has been particularly appreciated, allowing patients to regain mobility and participate more actively in daily activities.
However, the high cost of adalimumab remains a significant barrier for many Indian patients, limiting its accessibility despite its proven benefits. To address this issue, the introduction of biosimilars has provided a more affordable alternative, increasing the number of patients who can benefit from this treatment. Patients using biosimilar versions have reported similar therapeutic outcomes, making these options a valuable addition to the treatment landscape in India.
Therefore, get an overall knowledge of indian patient experience on adalimumab
See More Webinars @ Hidoc Webinars
1.
Inner Thoughts of Leonard Bernstein, the "Maestro".
2.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
3.
No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC
4.
Parents, teachers at Missouri school want answers after string of cancer diagnoses
5.
A promising medication could slow brain tumors in children.
1.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
2.
Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies
3.
Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances
4.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
5.
Generative AI for Adaptive Oncology Trial Design
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation